* Q32 Bio Inc QTTB.OQ QTTB.O is expected to show no
change in
quarterly revenue when it reports results for the period
ending December 31 2024
*
* LSEG's mean analyst estimate for Q32 Bio Inc is for a
loss of
$1.25 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 19.0%
in the last three months.
* Wall Street's median 12-month price target for Q32 Bio Inc
is
85.00, above its last closing price of $47.46.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -1.40 -1.40 -1.46 Missed -4
Jun. 30 0001 -1.05 -1.04 -1.42 Missed -36.2
Mar. 31 2024 -1.42 -2.32 -14.95 Missed -543.5
Dec. 31 2023 -5.40 -5.40 -5.04 Beat 6.7
Jan. -7.56 -7.56 -10.26 Missed -35.7
1 0001
Jun. 30 2023 -8.94 -8.55 -10.98 Missed -28.4
Jan. 1 0001 -9.71 -9.54 -9.00 Beat 5.7
Jan. 1 0001 -9.11 -9.07 -10.80 Missed -19.1
This summary was machine generated November 8 at 16:00 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)